Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity. If such virus is pathogenic to human and demonstrates the ability to transmit from person to person, the result is a global outbreak of disease that affects a high percentage of individuals in a short period of time and is likely to cause substantially increased mortality and morbidity in all countries of the world. Recently, purely avian influenza viruses, including the H5N1, H9N2 and H7N7 subtypes, have been directly transmitted to humans, raising concern over the possibility of a new influenza pandemic among the world's immunologically naive populations. In order to face this kind of situation, a pandemic influenza vaccine has to be developed.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)
Timeframe: At Day 10 post Dose 1
Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)
Timeframe: At Day 21 post Dose 1
Number of Seroconverted Subjects Against Influenza A Subtype H9N2
Timeframe: At Day 10 post Dose 1
Number of Seroconverted Subjects Against Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 1
Seroconversion Factor for Influenza A Subtype H9N2
Timeframe: At Day 10 post Dose 1
Seroconversion Factor for Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 1
Number of Seroprotected Subjects Against H9N2
Timeframe: At Day 10 post Dose 1
Number of Seroprotected Subjects Against H9N2
Timeframe: At Day 21 post Dose 1
Number of Subjects With Seroprotection Power Against H9N2
Timeframe: At Day 10 post Dose 1
Number of Subjects With Seroprotection Power Against H9N2
Timeframe: At Day 21 post Dose 1
Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)
Timeframe: At Day 21 post Dose 2 (Day 42)
Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)
Number of Seroconverted Subjects Against Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 2 (Day 42)
Number of Seroconverted Subjects Against Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)
Seroconversion Factor for Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 2 (Day 42)
Seroconversion Factor for Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)
Number of Seroprotected Subjects Against H9N2
Timeframe: At Day 21 post Dose 2 (Day 42)
Number of Seroprotected Subjects Against H9N2
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)
Number of Subjects With Seroprotection Power Against H9N2
Timeframe: At Day 21 post Dose 2 (Day 42)
Number of Subjects With Seroprotection Power Against H9N2
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)